Bremsstrahlung parameters of praseodymium-142 in different human tissues: A dosimetric perspective for 142Pr radionuclide therapy

Annals of Nuclear Medicine

Volumn 26, Issue 5, 2012, Pages 412-418

  Bakht, Mohamadreza K ^a   Jabal Ameli, Hamidreza ^a   Ahmadi, Seyed J ^b   Sadeghi, Mahdi ^b   Sadjadi, Sodeh ^b   Tenreiro, Claudio ^c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

^c Sungkyunkwan University   (South Korea)

Author keywords

Bremsstrahlung production; Human tissues; Praseodymium 142; Radionuclide therapy

Indexed keywords

PRASEODYMIUM 142; RADIOISOTOPE; UNCLASSIFIED DRUG; PRASEODYMIUM;

ADIPOSE TISSUE; ARTICLE; BLOOD; BONE MARROW; BRAIN; BREAST; BREMS RADIATION; BREMSSTRAHLUNG PARAMETERS; CARTILAGE; CONTROLLED STUDY; CORTICAL BONE; DOSIMETRY; GASTROINTESTINAL TRACT; HEART; HUMAN; HUMAN TISSUE; KIDNEY; LENS; LYMPH; MONTE CARLO METHOD; MUSCLE; OUTPATIENT; OVARY; PANCREAS; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; SKELETON; SPLEEN; TESTIS; THYROID GLAND; ANTIBODY SPECIFICITY; FEMALE; IMAGING PHANTOM; MALE; RADIOMETRY;

FEMALE; HUMANS; MALE; ORGAN SPECIFICITY; PHANTOMS, IMAGING; PRASEODYMIUM; RADIOISOTOPES; RADIOMETRY;

EID: 84862675618     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0591-6     Document Type: Article

References (29)

1. Bakht MK, Sadeghi M, Tenreiro C. A novel technique for simultaneous diagnosis and radioprotection by radioactive cerium oxide nanoparticles: study of cyclotron production of 137mCe. J Radioanal Nucl Chem. 2011. doi:10.1007/s10967-011-1483-2.
2. Mushtaq A. Reactors are indispensable for radioisotope production. Ann Nucl Med. 2010;24:759-60.
3. Hoefnagel CA. Radionuclide cancer therapy. Ann Nucl Med. 1998;12:61-70. (Pubitemid 28259383)
4. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med. 2005;46:4-12.
5. Sadeghi M, Enferadi M, Shirazi A. External and internal radiation therapy: past and future directions. J Can Res Ther. 2010;6:239-48.
6. 143Pr for radionuclide therapy (RNT) applications. In: Proceedings of the 5th international conference on isotopes (5ICI), Brussels, Belgium, 25-29 April 2005. p. 103-107.
7. 142Pr]-DTPA for application in radionuclide therapy. In: Proceedings of the 5th international conference on isotopes (5ICI), Brussels, Belgium, 25-29 April 2005. p. 521-526.
8. 142Pr hydroxyapatite crystals: a potential therapeutic agent for radiosynovectomy. Abstracts of SNMICON 2002. Indian J Nucl Med. 2002; 2002(17):7-8.
9. 142Pr: a potential for therapeutic applications and biodistribution studies. J Radioanal Nucl Chem. 2011;288:937-42.
10. 142Pr glass seeds for brachytherapy. Appl Radiat Isot. 2008;66:441-9. (Pubitemid 351288534)
11. 142Pr glass seeds for the brachytherapy of prostate cancer. Doctoral dissertation, Texas A&M University. http://hdl.handle.net/1969.1/ 5738. Accessed 17 Sep 2007.
12. Bakht MK, Sadeghi M. Internal radiotherapy techniques using radiolanthanide praseodymium-142: a review of production routes, brachytherapy, unsealed source therapy. Ann Nucl Med. 2011;25:529-35.
13. 142Pr microspheres as a potential treatment for arteriovenous malformations. Phys Med Biol. 2005;50:151-66.
14. Lee SW. Beta dose calculation in human arteries for various brachytherapy seed types. Doctoral dissertation, Texas A&M University. http://hdl.handle.net/1969.1/42. Accessed 30 Sep 2004.
15. Manjunatha HC, Rudraswamy B. Exposure of bremsstrahlung from beta-emitting therapeutic radionuclides. Radiat Meas. 2009;44:206-10.
16. Manjunatha HC, Rudraswamy B. Bremsstrahlung exposure of tissues from beta-therapeutic nuclides. Nucl Instrum Methods A. 2010;621:581-9.
17. Manjunatha HC, Rudraswamy B. Beta induced Bremsstrahlung exposure in DNA and RNA. Phys Med. 2011;27:188-93.
18. Monte Carlo Codes Group. MCNP-A general Monte Carlo n-particle Transport Code-Version 5, Los Alamos National Laboratory. http://mcnp-green.lanl.gov/ index.html. Accessed 29 Jan 2004.
19. Sadeghi M, Taghdiri F, Hoseini H, Tenreiro C. Monte Carlo calculated TG-60 dosimetry parameters for the b-emitter 153Sm brachytherapy source. Med Phys. 2010;37:5370-5.
20. Turner J. Atoms, radiation, and radiation protection. New York: Pergamon Press; 1986. p. 90.
21. National Council on Radiation Protection and Measurements. Precautions in the management of patients who have received therapeutic amounts of radionuclides. NCRP Report No. 37. Bethesda: National Council on Radiation Protection and Measurement; 1970.
22. Nuclear Regulatory Commission. Release of patients administered radioactive materials. Regulatory Guide 8.39. Washington: US Nuclear Regulatory Commission; 1997.
23. Zanzonico PB, Binkert BL, Goldsmith SJ. Bremsstrahlung radiation exposure from pure p-ray emitters. J Nucl Med. 1999;40: 1024-8. (Pubitemid 29269225)
24. Markowicz AA, VanGriken RE. Composition dependence of Bremsstrahlung background in electron-probe X-ray microanalysis. Anal Chem. 1984;56:2049e55.
25. Shivaramu. Modified Kramer's law for Bremsstrahlung produced by complete beta particle absorption in thick targets and compounds. J Appl Phys. 1990;68:1225-8.
26. Zanzonico PB, Barbara BL, Goldsmith SJ. Bremsstrahlung exposure from pure beta emitters. J Nucl Med. 1999;40:1024-30.
27. Johns HE, Cunningham JR. The physics of radiology. 3rd ed. Spingfield: Charles C Thomas; 1969. p. 164.
28. Mohan R, Antolak J. Monte Carlo techniques should replace analytical methods for estimating dose distributions in radiotherapy treatment planning. Med Phys. 2001;28:123-6. (Pubitemid 32165746)
29. 90Y bremsstrahlung emission computed tomography using gamma cameras. Ann Nucl Med. 2009;23:257-67.